Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 3, 2006, Pages 1108-1117

  Broad, Lisa M ^a   Zwart, Ruud ^a   Pearson, Kathy H ^a   Lee, Martin ^a   Wallace, Louise ^a   McPhie, Gordon I ^a   Emkey, Renee ^a,b   Hollinshead, Sean P ^a   Dell, Colin P ^a   Baker, S Richard ^a   Sher, Emanuele ^a  

^a ELI LILLY AND COMPANY   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 AMINO 5 KETO)THIAZOLE DERIVATIVE; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; [2 (4 FLUOROPHENYLAMIN) 4 METHYLTHIAZOL 5 YL) 4 TOLYLMETHANONE; [2 (4 FLUOROPHENYLAMINO) 4 METHYL THIAZOL 5 YL]THIPHEN 3 YL METHANONE; ACETYLCHOLINESTERASE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; BENZO[1,3] DIOXO 5 YL [2 (4 FLUOROPHENYLAMINO) 4 METHYLTHIAZOL 5 YL METHANONE; CYTISINE; EPIBATIDINE; N METHYL 4 [3 (5 ETHOXYPYRIDIN)YL] 3 BUTEN 1 AMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; SEROTONIN; TC 2559; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL CELL; ARTICLE; CHIMERA; CHOLINESTERASE INHIBITION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MAMMAL CELL; NONHUMAN; OOCYTE; PRIORITY JOURNAL; XENOPUS;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE; DRUG SYNERGISM; GALANTAMINE; HUMANS; NICOTINIC AGONISTS; PROTEIN SUBUNITS; PYRIDINES; RECEPTORS, NICOTINIC; RECOMBINANT PROTEINS; XENOPUS LAEVIS;

EID: 33747597579     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.104505     Document Type: Article

References (40)

1. Astles PC, Baker SR, Boot JR, Broad LM, Dell CP, and Keenan M (2002) Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands. Curr Drug Targets CNS Neuro Disord 1:337-348.
2. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
3. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, and Perry E (2001) Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49:175-184.
4. Craig PJ, Bose S, Zwart R, Beattie RE, Folly EA, Johnson LR, Bell E, Evans NM, Benedetti G, Pearson KH, et al. (2004) Stable expression and characterisation of a human α7 nicotinic subunit chimera: a tool for functional high-throughput screening. Eur J Pharmacol 502:31-40.
5. Curtis L, Buisson B, Bertrand S, and Bertrand D (2002) Potentiation of human α4β2 neuronal nicotinic acetylcholine receptor by estradiol. Mol Pharm 61:127-135.
6. Dani JA (2001) Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 49:166-174.
7. Eisele J-L, Bertrand S, Galzi J-L, Devillers-Thlery A, Changeux J-P, and Bertrand D (1993) Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature (Lond) 366:479-483.
8. Ellman GL, Courtney KD, Andres V, and Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
9. Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, Laville M, Reibaud M, Pradier L, Dunbar G, et al. (2004) TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev 10:147-166.
10. Gu Q and Moss RL (1996) 17β-Estradiol kainate-induced currents via activation of the cAMP cascade. J Neurosci 16:3620-3629.
11. Hogg RC, Buisson B, and Bertrand D (2005) Allosteric modulation of ligand-gated ion channels. Biochem Pharm 70:1267-1276.
12. A receptor-channel complex in dorsal root ganglion neurons. Neuropharmacology 35:1251-1261.
13. Hurst RS, Hajos M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas MB, Hoffmann WE, Piotrowski DW, et al. (2005) A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterisation. J Neurosci 25:4396-4405.
14. 4 receptor channels. J Neurosci 19:7289-7299.
15. 3 receptor-mediated ion current in N1E-115 neuroblastoma cells. B J Pharmacol 108:287-289.
16. Krause RM, Buisson B, Bertrand S, Corringer P-J, Galzi J-L, Changeux J-P, and Bertrand D (1998) Ivermectin: a positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:283-294.
17. Leonard S, Breese C, Adams C, Benhammou K, Gault J, Stevens K, Lee M, Adler L, Olincy A, Ross R, et al. (2000) Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur J Pharmacol 393:237-242.
18. Levin ED and Rezvani AH (2000) Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol 393:141-146.
19. Levandoski MM, Piket B, and Chang J (2003) The anthelmintic levamisol is an allosteric modulator of human neuronal nicotinic acetylcholine receptors. Eur J Pharmacol 471:9-20.
20. Lindstrom J (2000) The structures of neuronal nicotinic receptors, in Neuronal Nicotinic Receptors, Handbook of Experimental Pharmacology (Clementi F, Fornasari D, and Gotti C eds.) vol 144, pp 101-162, Springer-Verlag, New York.
21. Lloyd GK and Williams M (2000) Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 292:461-467.
22. Lippiello PM, Bencherif M, Gray JA, Peters S, Grigoryan G, Hodges H, and Collins AC (1996) RJR-2403: a nicotinic agonist with CNS selectivity: II. In vivo characterization. J Pharmacol Exp Ther 279:1422-1429.
23. Maelicke A, Schrattenholz A, Samochocki M, Radina M, and Albuquerque EX (2000) Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 113:199-206.
24. McGehee DS and Role LW (1995) Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurones. Annu Rev Physiol 57:521-546.
25. Meyer EM, Tay ET, Papke RL, Meyers C, Huang GL, and de Fiebre CM (1997) 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res 768:49-56.
26. Moghul S and Wilkinson D (2001) Use of acetylcholinesterase inhibitors in Alzheimer's disease. Exp Rev Neurother 1:61-69.
27. Moriguchi S, Marszalec W, Zhao X, Yeh JZ, and Narahashi T (2004) Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther 310:933-942.
28. Oyaizu M and Narahashi T (1999) Modulation of the neuronal nicotinic acetylcholine receptor channel by the nootropic drug nefiracetam. Brain Res 822:72-79.
29. Paradiso K, Zhang J, and Steinbach JH (2001) The C terminus of the human nicotinic α4β2 receptor forms a binding site required for potentiation by an estrogenic steroid. J Neurosci 21:6561-6568.
30. Pereira EF, Alkondon M, Reinhardt S, Maelicke A, Peng X, Lindstrom J, Whiting P, and Albuquerque EX (1994) Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 270:768-778.
31. Pereira EF, Hilmas C, Santos MD, Alkondon M, Maelicke A, and Albuquerque EX (2002) Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 53:479-500.
32. Quik M and Kulak JM (2002) Nicotine and nicotinic receptors: relevance to Parkinson's disease. Neurotoxicology 23:581-594.
33. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EFR, et al. (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305:1024-1036.
34. Shan Q, Haddrill JL, and Lynch JW (2001) Ivermectin, an unconventional agonist of the glycine receptor chloride channel. J Biol Chem 276:12556-12564.
35. Sher E, Chen Y, Sharples TJW, Broad LM, Benedetti G, Zwart R, McPhie GI, Pearson KH, Baldwinson T, and De Filippi G (2004) Physiological roles of neuronal nicotinic receptor subtypes: new insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity. Curr Topics Med Chem 4:283-297.
36. Sher E, Zwart R, De Filippi G, Baldwinson T, Pearson KH, McPhie GI, Keenan M, O'Neill MJ, Fucile S, and Broad LM (2005) Pharmacological and electrophysiological characterisation of a new class of selective α7 nicotinic receptor allosteric potentiators. Society Neurosci Abstr 951.10; 2005 Nov 12-16; Society of Neuroscience, Washington, DC.
37. Woodruff-Pak DS, Lander C, and Geerts H (2002) Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev 8:405-426.
38. Yoshii M and Watabe S (1994) Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384) in NG108-15 cells. Brain Res 642:123-131.
39. Zuo Y, Aistrup GL, Marszalec W, Gillespie A, Chavez-Noriega LE, Yeh JZ, and Narahashi T (2001) Dual action of n-alcohols on neuronal nicotinic acetylcholine receptors. Mol Pharmacol 60:700-711.
40. Zwart R, De Filippi G, Broad LM, McPhie GI, Pearson KH, Baldwinson T, and Sher E (2002) 5-Hydroxyindole potentiates human α7 nicotinic receptor-mediated responses and enhances acetylcholine-induced glutamate release in cerebellar slices. Neuropharmacology 43:374-384.